Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls.
Longer survivial in childhood leukemia prompted this study of pubertal development and reproductive function in 35 girls and women. Twenty-eight patients (80 per cent) had normal pubertal progression during a median of 74 months after diagnosis of leukemia and 49 months of chemotherapy. Seven patients were abnormal: four exhibited hypothalamic-pituitary dysfunction with suppression of circulating serum gonadotropins (less than 6 mlU per milliliter); three others had evidence of primary ovarian dysfunction - reversible in two - with inappropriately elevated circulating serum gonadotropins (follicle-stimulating hormone greater than 20 mlU per milliliter). Normal sexual development correlated best with pubertal status at onset of leukemia; only one of 17 patients with diagnosis before puberty experienced altered pubertal progression, whereas abnormalities appeared in six of 18 with onset during puberty or after menarche. Thus, most girls with aggressively treated child-hood leukemia have an excellent prognosis for normal hypothalamic-pituitary-ovarian function; normal development is further enhanced in patients who are prepubertal at onset of leukemia.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007231:Infant, Newborn; D007938:Leukemia / Q000188:drug therapy / Q000503:physiopathology*; D008572:Menarche / Q000187:drug effects; D010053:Ovary / Q000503:physiopathology; D011247:Pregnancy; D011379:Prognosis; D011627:Puberty / Q000187:drug effects; D012098:Reproduction / Q000187:drug effects; D013997:Time Factors
D000970:Antineoplastic Agents; D006065:Gonadotropins, Pituitary; D005640:Follicle Stimulating Hormone